← Leaderboards
Young-Mee Park
Roswell Park Cancer Institute Corp
$3,108,922
Attributed
$3,108,922
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $839.2K · FY2005–11$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$3,108,922 · 3
By mechanism
R01$1,606,132 · 2
P01$1,502,790 · 1
Top collaborators
No co-investigators on record.
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- David G Kirsch$23,601,785
- Clement C Ip$9,662,404
- Cameron Riker Macdonald$169,092
- Daniel Michael Green$92,024
Others in their field
Top investigators on “Human Tissue”
- David Heimbrook · Leidos Biomedical Research, Inc.$294,443,261
- Lawrence Corey · Fred Hutchinson Cancer Center$212,638,156
- Larry Arthur$131,303,476
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$114,079,276
- Peter Gordon Gillespie · Oregon Health And Science University$104,808,120
- Kevin Urdahl · Seattle Children'S Hospital$85,664,942
Research focus
Human TissueTranscription FactorApoptosisStressResistanceTumorOxidation-ReductionProtein FamilyMemberMolecularBaseResponseMalignant NeoplasmsCancer CellProteinsRegulationAffectCellsFamilyCell SurvivalCell Culture SystemIn VitroBlood VesselsApoptotic
Grant awards (11)
HYPOXIA AND PRX1 IN FINASTERIDE AND SELENIUM INTERVENTION OF PROSTATE CANCER$301,313
P01 · FY2011 · CA · contact PI
HYPOXIA AND PRX1 IN FINASTERIDE AND SELENIUM INTERVENTION OF PROSTATE CANCER$310,417
P01 · FY2010 · CA · contact PI
HYPOXIA AND PRX1 IN FINASTERIDE AND SELENIUM INTERVENTION OF PROSTATE CANCER$304,113
P01 · FY2009 · CA · contact PI
HYPOXIA AND PRX1 IN FINASTERIDE AND SELENIUM INTERVENTION OF PROSTATE CANCER$295,045
P01 · FY2008 · CA · contact PI
Prx1 in malignant progression of prostate cancer$303,158
R01 · FY2007 · CA · contact PI
HYPOXIA AND PRX1 IN FINASTERIDE AND SELENIUM INTERVENTION OF PROSTATE CANCER$291,902
P01 · FY2007 · CA · contact PI
Peroxiredoxin 1 in radiotherapy of lung cancer$244,168
R01 · FY2007 · CA · contact PI
Prx1 in malignant progression of prostate cancer$308,289
R01 · FY2006 · CA · contact PI
Peroxiredoxin 1 in radiotherapy of lung cancer$248,799
R01 · FY2006 · CA · contact PI
Peroxiredoxin 1 in radiotherapy of lung cancer$252,143
R01 · FY2005 · CA
Peroxiredoxin 1 in radiotherapy of lung cancer$249,575
R01 · FY2004 · CA